Chandra Bartholomeusz, M.D., Ph.D.
Department of Breast Medical Oncology, Division of Cancer Medicine
About Dr. Chandra Bartholomeusz
I have a strong background in translational breast cancer research in the areas of cancer biology and molecular therapeutics and signaling in breast cancer. Ihave shown that PEA-15, a novel phosphoprotein, has tumor suppressor properties in both breast and ovarian cancer, binds and inhibits ERK, and correlates with longer overall survival in patients with ovarian cancer. The overall goal of the proposed research is the development of noveltargeted therapy inhibiting tumorigenicity and metastasis by development of PEA-15-AA as a therapeutic agent in TNBC and using Wnt/β-catenin as a predictive biomarker; and the development of these agents into clinical strategies for patients with TNBC. I can provide my expertise in breast cancer biology pertaining to the MAPK pathway documented by my peer-reviewed publications and research grants from public and private funding agencies.
Present Title & Affiliation
Primary Appointment
Associate Professor (Tenured), Department of Breast Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, MD Anderson UTHealth Houston Graduate School, Department of Graduate School of Biomedical Sciences, MD Anderson UTHealth Houston Graduate School
Dual/Joint/Adjunct Appointment
Associate Professor (Tenured), Department of Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, Department of Graduate School of Biomedical Sciences, The University of Texas -UTHealth Houston/MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2004 | The University of Texas, Graduate School of Biomedical Sciences - Health Science Center and MD Anderson Cancer Center, Houston, Texas, US, PhD in Cancer Biology - Molecular Biology |
| 1986 | University of Zambia, Lusaka, ZM, MD |
| 1983 | University of Zambia, Lusaka, ZM, BS (Human Biology) |
Postgraduate Training
| 2008-2009 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2008 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston |
| 2000-2004 | Graduate Research Assistant, Cancer Biology and Molecular Biology, University of Texas, Houston, Texas |
| 1993-1997 | Graduate Teaching Assistant, Microbiology-Molecular Biology, University of Oklahoma, Norman, Oklahoma |
| 1986-1987 | Rotating Clinical Internship, University Teaching Hospital, Lusaka |
Experience & Service
Faculty Academic Appointments
Assistant Professor - Tenure Track, Department of Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Assistant Professor - NTR, Department of Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2013
Instructor, Department of Breast Medical Oncology-Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2009 - 2010
Administrative Appointments/Responsibilities
Co-Director -Middle School Program, Summer Experience Programs, Department of Education and Training, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2023
Faculty Liaison for Summer Experience Programs, Department of Education and Training, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2023
Co-Director -Summer Undergraduate Research Program (SURP) and Outreach Programs(OP) under the umbrella of the Summer Experience Programs, Department of Education and Training, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2023
Chief Ad Interim for of the Section of Translational Breast Cancer Research, Department of Breast Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2017
Other Professional Positions
Research Assistant, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997 - 2000
Medical Student Elective in Pediatrics, St. Bartholomew's Hospital, London, 1985 - 1985
Medical Student Research Assistant, The University of Zambia and World Health Organization Tropical Diseases Research Center, Ndola, 1985
Medical Student Research Assistant, University Teaching Hospital, 1985
Intramural Institutional Committee Activities
Committee Member, GSBS Executive Committee, MD Anderson UTHealth Graduate School of Biomedical Sciences, 2024 - Present
Extramural Institutional Committee Activities
BMO Search Committee, Interviewed Dr. Raissa Kentsa, The University of Texas MD Anderson Cancer Center, 2025
Member, BMO Chair Advisory Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2025
Chair, Graduate School of Biomedical Sciences (GSBS )Scholarship Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Reviewer, NCI F99/K00 Award Nominee Selection Meeting, The University of Texas MD Anderson Cancer Center, 2024
Judge, Therapeutics and Pharmacology Program Retreat, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, 2024
Committee Member, Mentorship Committee - Dr. Simone Anfossi, The University of Texas MD Anderson Cancer Center, 2024 - Present
Reviewer, 2024 Graduate Student Research Day (GSRD), The University of Texas MD Anderson Cancer Center, 2024
Reviewer, Division of Cancer Medicine (DoCM) Employee Recognition & Awards Program, The University of Texas MD Anderson Cancer Center, 2024
Reviewer, Trainee Research Day (TRD), The University of Texas MD Anderson Cancer Center, 2024 - 2024
Co-Director, Co-Director GSBS TAP Core Course, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Research Integrity Inquiry Committee Meeting, The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Member, Therapeutics and Pharmacology (TAP) Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2026
Faculty Representative, Graduate Education Committee (GEC), The University of Texas MD Anderson Cancer Center, 2023 - Present
Judge - Poster, 2023 Graduate Student Research Day (GSRD), The University of Texas MD Anderson Cancer Center, 2023
Reviewer, Research Faculty Appointment - Promotion Committee, The University of Texas MD Anderson Cancer Center, 2023
Committee Member, GSBS Student Scholarship Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Judge, Trainee Research Day (TRD), The University of Texas MD Anderson Cancer Center, 2022
Committee Member, Inflammatory Breast Cancer Executive Team, The University of Texas MD Anderson Cancer Center, 2022 - Present
Committee Member, BReaST service phase I protocol REView (BRSTRev), The University of Texas MD Anderson Cancer Center, 2022 - Present
Reviewer, 31st Keck Annual Research Conference Poster Session, The University of Texas MD Anderson Cancer Center, 2021
Committee Member, Odyssey Program Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Reviewer, 2020 TAP Virtual Program Retreat Oral Presentation, The University of Texas MD Anderson Cancer Center, 2020
Committee Member, Scientific Review Committee 4 (SRC 4), The University of Texas MD Anderson Cancer Center, 2020 - 2024
Committee Member, Faculty Educator of the Year Selection Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Reviewer, Distinguished Faculty Mentor Award, The University of Texas MD Anderson Cancer Center, 2019
Co-Chair, Postdoctoral Advisory Committee (PDAC), The University of Texas MD Anderson Cancer Center, 2019 - 2020
Reviewer, SINF (Global Academic Programs) committee, The University of Texas MD Anderson Cancer Center, 2019
Faculty Judge- Oral Presentation Clinical/Translational Science:, APSS (Annual Postdoctoral Science Symposium), The University of Texas MD Anderson Cancer Center, 2019
Reviewer, ARC- 2019 ConTex Postdoctoral Fellowships, The University of Texas MD Anderson Cancer Center, 2019
Committee Member, Inflammatory Breast cancer Seminar Series, The University of Texas MD Anderson Cancer Center, 2019 - Present
Chair - Ad Interim, Academic Standards Committee, The University of Texas MD Anderson Cancer Center, 2019
Reviewer, 2019 Internal Medicine Employee Excellence Awards, The University of Texas MD Anderson Cancer Center, 2019
Faculty Member Reviewer, Faculty Academic Review Committee (Faculty ARC), The University of Texas MD Anderson Cancer Center, 2019 - 2022
Committee Member, Student and Trainee Leadership Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Committee Member, IBC Wranglers Boot Walk Planning, Morgan Welch Inflammatory Breast Cancer Program and Clinic, 2019 - Present
Faculty Member, Postdoctoral Advisory Committee (PDAC), The University of Texas MD Anderson Cancer Center, 2018 - 2021
Retreat Judge - Oral Presentation, TAP (Therapeutics & Pharmacology) 9th Annual Program Retreat, The University of Texas MD Anderson Cancer Center, 2018
Faculty Judge, Trainee Recognition Day - Endowed Fellowship Events, The University of Texas MD Anderson Cancer Center, 2018 - 2018
Faculty Judge, Trainee Recognition Day - Oral Competition of Translational Research, The University of Texas MD Anderson Cancer Center, 2018
Judge, 59th Annual National Student Research Forum, The University of Texas MD Anderson Cancer Center, 2018
Member, Academic Standards Committee -GSBS, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Faculty Judge -Abstracts and Posters, 7th Annual Postdoctoral Science Symposium (APSS), The University of Texas MD Anderson Cancer Center, 2017
Poster Judge, GSBS Student Research Day (GSRD), The University of Texas MD Anderson Cancer Center, 2017
Judge, GSBS Annual Oral Presentaion Skill Competetion, The University of Texas MD Anderson Cancer Center, 2016
Department Research Leader representing Chair when out of office, DOCM and Executive Council Meeting (IREC), The University of Texas MD Anderson Cancer Center, 2014 - 2019
Representative for Breast Medical Oncology Department (Awarded Incucyte as Capital Equipment in 2016), Research Capital Equipment Prioritizing Committee, The University of Texas MD Anderson Cancer Center, 2014
Panel Member, Appeal Hearing Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2013
Faculty Representative for Department (Awarded Time-Lapse Microscope and Incucyte)), Research Capital Equipment Prioritizing Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2016
Member, Scientific Publications Advisory Group, The University of Texas MD Anderson Cancer Center, 2006 - 2019
Committee Member, Cancer Biology Retreat Organizing Committee, The University of Texas MD Anderson Cancer Center, 2004
Editorial Activities
Member Editorial Advisory Board, Medical Hypothesis, 2012 - Present
Honors & Awards
| 2024 - Present | ACS Catalyst Award, ACS |
| 2024 | Awesome Job Award - Panelist for DoCM Employee Recognition & Awards Program FY24 Citation for Excellence Awards, DoCM - Claire Blondeau |
| 2023 | Department of Defense (Breast cancer Research Program-Breakthrough Award-Level 2), Department of Defense |
| 2021 | LEADing Others Accelerate, Leadership Institute at MD Anderson Cancer Center |
| 2021 | Bootwalk to End Cancer - Co-Captain IBC Wrangler Team, MD Anderson Cancer Center |
| 2019 | Highlighted as an ACS funded researcher, American Cancer Society |
| 2019 | AAMC Mid- Career Women Faculty Leadership Development Seminar selected Participant, Association of American Medical Colleges |
| 2018 | American Cancer Society Research Scholar Award, American Cancer Society |
| 2017 | Commitment to Mentoring Award, MD Anderson Cancer Center - Awarded by Dr.Lara Carolina Landry |
| 2012 | AAMC Early Career Women Faculty Professional Development Seminar selected Participant, Association of American Medical Colleges |
| 2011 | Annual Division of Cancer Medicine Research Awards Program Winner of Research Award for academic excellence (3rd Place), The University of Texas MD Anderson Cancer Center |
| 2009 | K99/ROO Pathway to Independence Award, NIH/NCI |
| 2009 | AACR –WICR (American Association of Cancer Research - Women In Cancer Research) Scholar-in-Training Award, American Association of Cancer Research |
| 2007 | Bristol-Myers Squibb Award in Clinical Translational Research Poster Winner (1st place), Trainee Recognition Day, The University of Texas MD Anderson Cancer Center |
| 2007 | The Linda K. Manning Fellowship in Ovarian Cancer Research, The University of Texas MD Anderson Cancer Center |
| 2006 | Postdoctoral Fellowship -Susan G. Komen Breast Cancer Foundation, Susan G. Komen Breast Cancer Foundation |
| 2006 | The Diane Denson Tabola Fellowship in Ovarian Cancer Research, The University of Texas MD Anderson Cancer Center |
| 2005 | BettyAnn Asche-Murray Fellowship, The University of Texas MD Anderson Cancer Center |
| 2004 | Scientific Excellence Award in the Post Candidacy Category First Place Winner (Abstract-Oral Presentation), Graduate School of Biomedical Sciences-Cancer Biology Retreat, University of Texas Health Science Center |
| 2003 - 2004 | Travel Award, Graduate School of Biomedical Sciences-University of Texas Health Science Center |
| 2002 | Honorable mention top 10% abstracts, Trainee Recognition Day, The University of Texas MD Anderson Cancer Center |
| 2002 | Research Experience Fellowship in Summer Program for U.S. Graduate Students in Science and Engineering to conduct research in Japan, National Science Foundation of US/Ministry of Education, Ministry of Culture, Sports, Science and Technology of Japan |
| 1995 | Cleo Cross International Scholarship Award, University of Oklahoma |
| 1993 - 1997 | Graduate College Merit Tuition/Fee Waiver Award, University of Oklahoma |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. My Professional Journey Through Career, Affiliations, and Research. Gulf Coast Consortium Training Interdisciplinary Pharmaceutical Scientists (TIPS) Fellowship Lecture, US.
- 2025. Flash-Talk Competition - Dr. Mohd Mughees was selected to present his research on the MELK Project - Won Third Place for translational research. Invited. MD Anderson Postdoctoral Association - Trainee Day as part of MD Andersons 2025 Education Week, US.
- 2024. How to Give an Effective Chalk Talk. Invited. Houston, TX, US.
- 2024. Identification and Validation of a Novel Biologic Target DKK1 in Triple-Negative and Inflammatory Breast Cancer. Leap Therapeutics. Houston, Texas, US.
- 2023. Philanthropy at MWIBC Program - Bootwalk 2023. 1000 IBC patient Event. Houston, Texas, US.
- 2023. Role of a Novel Second-generation MELK-Selective inhibitor in IBC (Bootwalk Funding). IBC Research Seminar Meeting. Houston, Texas, US.
- 2023. Novel second-generation selective MELK inhibitor reduces tumor growth in a triple-negative inflammatory breast cancer xenograft model - Mentor of Dr. Mughees Mohd. Invited. 2023 Trainee Recognition Day - Dr. Mughees Mohd received first place in the category of Translational Research and gave a Oral Presentation. Houston, Texas, US.
- 2023. Triple Negative Breast cancer - ACS Funded Researcher. Invited. Triple Negative Breast cancer - ACS Funded Researcher. Houston, TX, US.
- 2022. MELK: a driver of tumor progression and as a therapeutic target in aggressive breast cancers. Invited. MELK: a driver of tumor progression and as a therapeutic target in aggressive breast cancers. Houston, TX, US.
- 2022. Therapeutic potential of second-generation MELK-selective inhibitor in aggressive breast cancers. Conference. Therapeutic potential of second-generation MELK-selective inhibitor in aggressive breast cancers. Houston, TX, US.
- 2022. Research Spotlights from MD Anderson. Invited. Research Spotlights from MD Anderson. Houston, TX, US.
- 2022. Determine the Biological Role of Mcl1 in Inflammatory Breast Cancer. Invited. Determine the Biological Role of Mcl1 in Inflammatory Breast Cancer. Houston, TX, US.
- 2022. Targeting MELK in aggressive cancers - How to Revise the Grant Proposal for Resubmission. Invited. Targeting MELK in aggressive cancers - How to Revise the Grant Proposal for Resubmission. Houston, TX, US.
- 2021. Succeeding in Academic Science: Navigating the Scholastic Research Track. Invited. Succeeding in Academic Science: Navigating the Scholastic Research Track. Houston, TX, US.
- 2020. Sailing to the Next Port. Invited. Sailing to the Next Port. Houston, TX, US.
- 2020. Current areas of Research interests in the Bartholomeusz Laboratory. Invited. Current areas of Research interests in the Bartholomeusz Laboratory. Houston, TX, US.
- 2020. Maternal embryonic leucine zipper kinase (MELK) a molecular driver in Aggressive Breast Cancers. Invited. Maternal embryonic leucine zipper kinase (MELK) a molecular driver in Aggressive Breast Cancers. Houston, TX, US.
- 2019. Navigating the Path to an Academic Career and Early Career Funding Opportunities. Conference. Navigating the Path to an Academic Career and Early Career Funding Opportunities. Houston, TX, US.
- 2019. Grand Writing Tips. Conference. Grand Writing Tips. Houston, TX, US.
- 2019. Panel Member on Career Development Annual MD/PhD Retreat. Conference. Panel Member on Career Development Annual MD/PhD Retreat. Houston, TX, US.
- 2019. Targeting the MEK-ERK-PEA-15 Cascade in Triple Negative Breast Cancer. Invited. Targeting the MEK-ERK-PEA-15 Cascade in Triple Negative Breast Cancer. Houston, TX, US.
- 2018. How to Navigate Academia – Career Path Seminar series. Invited. How to Navigate Academia – Career Path Seminar series. Houston, TX, US.
- 2018. Lab Introductions and Discussion portion. Invited. Lab Introductions and Discussion portion. Houston, TX, US.
- 2018. RCR Lecture: Rigor and Reproducibility. Invited. RCR Lecture: Rigor and Reproducibility. Houston, TX, US.
- 2018. Targeting the ERK/MEK/PEA-15 Pathway, understanding MEK Inhibitor Resistance and developing novel therapeutic agents that target Kinases in TNBC. Invited. Targeting the ERK/MEK/PEA-15 Pathway, understanding MEK Inhibitor Resistance and developing novel therapeutic agents that target Kinases in TNBC. Houston, TX, US.
- 2018. Update Bartholomeusz Laboratory Research. Invited. Update Bartholomeusz Laboratory Research. Houston, TX, US.
- 2016. MAPK signaling pathway: an emerging player in TNBC. Conference. MAPK signaling pathway: an emerging player in TNBC. Houston, TX, US.
- 2016. ERK Project. Invited. ERK Project. Houston, TX, US.
- 2016. BMO Education Seminar Series. Invited. BMO Education Seminar Series. Houston, TX, US.
- 2015. Women in Science and Medicine at MD Anderson Cancer Center. Invited. Women in Science and Medicine at MD Anderson Cancer Center. Houston, TX, US.
- 2015. Submitting a Competitive IRG Program Application. Invited. Submitting a Competitive IRG Program Application. Houston, TX, US.
- 2013. Identification of potential novel mechanisms of MEK Inhibitor Resistance in TNBC using a Genome-wide siRNA functional screen. Conference. Identification of potential novel mechanisms of MEK Inhibitor Resistance in TNBC using a Genome-wide siRNA functional screen. Houston, TX, US.
- 2013. Introduction to Research in BMO. Invited. Introduction to Research in BMO. Houston, TX, US.
- 2013. Core Skills. Invited. Core Skills. Houston, TX, US.
- 2012. Navigating the maze of federal funding. Invited. Lessons Learned from AAMC Early Career Faculty Development. Houston, Texas, US.
- 2012. Development of Targeted Therapy for ERK pathway in Triple-Negative Breast cancer. Invited. The University of Texas, MD Anderson Cancer Center. Houston, Texas, US.
- 2010. Transition from Postdoc to Faculty Member. Invited. Transition from Postdoc to Faculty Member. Houston, TX, US.
- 2009. GSBS Orientation outlining research in my mentors laboratory to recruit new graduate students. Invited. GSBS Orientation outlining research in my mentors laboratory to recruit new graduate students. Houston, TX, US.
- 2008. GSBS Orientation outlining research in my mentors laboratory to recruit new graduate students. Conference. GSBS Orientation outlining research in my mentors laboratory to recruit new graduate students. Houston, TX, US.
- 2004. Mechanism of E1A-induced Anti-tumor effect in Ovarian Cancer through PEA-15 (phospho-enriched in astrocytes. Invited. Mechanism of E1A-induced Anti-tumor effect in Ovarian Cancer through PEA-15 (phospho-enriched in astrocytes. Houston, TX, US.
Regional Presentations
- 2023. Therapeutic potential of second-generation MELK-selective inhibitor in aggressive breast cancers. Invited. MDACC & UT Austin Collaborative Research Summit, US.
- 2022. Discuss Breast Cancer Research funded by ACS. Invited. Discuss Breast Cancer Research funded by ACS, US.
- 2022. TNBC Research funded by ACS. Invited. TNBC Research funded by ACS, US.
- 2021. A Novel Second-generation MELK specific inhibitor targets triple negative inflammatory breast cancer (TN-IBC) - presented by Mentee Hector Gonzalez. Invited. A Novel Second-generation MELK specific inhibitor targets triple negative inflammatory breast cancer (TN-IBC) - presented by Mentee Hector Gonzalez. Hosuton, TX, US.
- 2020. What is cancer?" and "How does cancer research work?". Conference. What is cancer?" and "How does cancer research work?", US.
- 2015. Identification of potential novel mechanisms of MEK Inhibitor Resistance with TNBC using a Genome-wide siRNA functional screen. Invited. Identification of potential novel mechanisms of MEK Inhibitor Resistance with TNBC using a Genome-wide siRNA functional screen. Austin, TX, US.
National Presentations
- 2025. Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model. Poster. San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2025. MELK in Aggressive Breast Cancers: Bridging Basic Discovery with Clinical Impact. Invited. University of Texas McGovern Medical School’s Department of Integrative Biology and Pharmacology Seminar Series, US.
- 2025. Overcoming MEK inhibitor resistance in highly aggressive breast cancers by targeting MCL1, an anti-apoptotic protein. Invited. Cancer Biology Program. Honolulu, HI, US.
- 2024. Discovery and Validation of MELK in Triple-Negative and Inflammatory Breast Cancer: Implications for Therapeutic Intervention. Invited. Cancer Biology Seminar Series, Hawaii, US.
- 2022. Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers. Poster. Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers. San Antonio, TX, US.
- 2022. Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer. Conference. Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer. San Antonio, TX, US.
- 2022. Combination treatment with a MCL1 Inhibitor AZD5991 overcomes resistance to MEK inhibitor in TNBC cells. Poster. Combination treatment with a MCL1 Inhibitor AZD5991 overcomes resistance to MEK inhibitor in TNBC cells, LA, US.
- 2020. MAPK signaling pathway: an emerging player in TNBC. Conference. Sixth International Conference on Drug Discovery, Development and Lead Optimization, US.
- 2016. ERK Project, OLINKS. Conference. ERK Project, OLINKS. Houston, TX, US.
- 2015. High MELK expression levels correlate with shorter overall survival in breast cancer. Poster. 2015 Gordon Research Conference. W. Dover, VT, US.
- 2014. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in both HER2-overexpressing inflammatory and non-inflammatory breast cancer cells through FOXO3-mediated Bim1 expression. Poster. San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2014. Overview of Translational Research Findings. Invited. 4th International Inflammatory Breast Cancer Research Program and Clinic Collaborative Workshop, TX, US.
- 2014. Anti-proliferative and cytotoxic activities of 5-(nonyloxy)tryptamine derivates in breast cells. Poster. AACR Annual Meeting 2014. San Diego, CA, US.
- 2014. A novel covalent inhibitor targeting JNK signaling in triple-negative breast cancer. Poster. AACR Annual Meeting 2014. San Diego, CA, US.
- 2013. ERK2 rather than ERK1 contributes to EMT and metastatic potential in triple-negative breast cancer. Poster. AACR Annual Meeting 2013. Washington, DC, US.
- 2013. Preclinical development of JNK-targeted therapy for triple-negative breast cancer. Poster. AACR Annual Meeting 2013. Washington, DC, US.
- 2012. Selumetinib inhibits cancer stem cells by targeting the MAPK pathway in TNBC/IBC. Poster. 3rd Int'l IBC Conference. Philadelphia, PA, US.
- 2012. Targeting ERK as a Therapeutic Strategy for Triple-Negative Breast Cancer. Invited. Medical College of Wisconsin - Cancer Cell Biology Research Program. Milwaukee, WI, US.
- 2012. Targeting ERK as a Therapeutic Strategy for Triple-Negative Breast Cancer. Invited. University of South Alabama. Mobile, AL, US.
- 2012. Development of Targeted Therapy for ERK pathway in Triple-Negative Breast cancer. Invited. University of Oklahoma Health Sciences Center , Stephenson Cancer Center. Oklahoma, OK, US.
- 2012. Development of Targeted Therapy for ERK pathway in Triple-Negative Breast cancer. Invited. The University of Toledo. Toledo, OH, US.
- 2011. Development of Targeted Therapy for ERK pathway in Triple-Negative Breast cancer. Invited. Case Western Reserve University. Cleaveland, OH, US.
- 2011. ERK2 promotes stem-cell-like characteristics in triple-negative breast cancer -Poster Discussion. Invited. ERK2 promotes stem-cell-like characteristics in triple-negative breast cancer -Poster Discussion. San Antonio, TX, US.
- 2009. PEA-15 inhibits tumorigenesis in a breast cancer xenograft model by inhibiting tumor cell proliferation through increased cytoplasmic localization of activated ERK. Invited. AACR-WICR (Recipient of AACR-WICR Award). Denver, CO, US.
International Presentations
- 2025. Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model. Poster. CRO-Aviano & MD Anderson Joint Symposium on Cancer Biology and Precision Oncology, US.
- 2022. What is the Minimum Preclinical Requirement for Submitting a Clinical Trial LOI. Invited. 9th Clinical Research Skill Advancement Workshop, US.
- 2020. What is the Minimum Preclinical Requirement for Submitting a Clinical Trial LOI -The 8th Clinical Research Skill Advancement Workshop. Invited. The 8th Clinical Research Skill Advancement Workshop, US.
- 2019. What is the Minimum Preclinical Requirement for Submitting a Clinical Trial LOI -The 7th Clinical Research Skill Advancement Workshop. Invited. The 7th Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2018. What is the Minimum Preclinical Requirement for Submitting a Clinical Trial LOI -The 6th Clinical Research Skill Advancement Workshop. Invited. The 6th Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2017. Exploiting the MAPK Pathway to develop new treatment strategies for TNBC. Conference. Tools and Technologies of Precision Medicine. Capetown, ZA.
- 2017. MAPK signaling Pathway: an emerging player in TNBC. Keio University. Tokyo, JP.
- 2017. Biomarker Oriented Oncology drug development. Conference. Biomarker Oriented Oncology drug development. Osaka, JP.
- 2017. Bench to Bedside, 5th Clinical Research Skill Advancement Workshop. Conference. Bench to Bedside, 5th Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2016. Is the MAPK pathway targeting an Emerging treatment strategy for Triple-Negative Breast cancer. Invited. Second International Conference on natural Product Genomics and Drug Discovery. Colombo, LK.
- 2016. Bench to Bedside -4th Clinical Research Skill Advancement Workshop. Conference. Bench to Bedside -4th Clinical Research Skill Advancement Workshop. Tokyo, JP.
- 2014. ERK2, but not ERK1, promotes cancer stem cell-like characteristics and EMT in triple-negative breast cancer. Conference. 2014 Gordon Research Conference. Lucca, IT.
- 2013. Targeting ERK as a Therapeutic Strategy for Triple-Negative Breast Cancer. Kyoto University - Department of Target Therapy Oncology. Kyoto, JP.
Formal Peers
- 2017. MAPK signaling pathway: an emerging player in TNBC. Invited. Tokyo, JP.
- 2016. Is targeting the MAPK pathway an emerging treatment strategy for Triple Negative Breast Cancer. Invited. Colombo, LK.
- 2016. Bench to Bedside. Invited. Tokyo, JP.
- 2013. Targeting the MAPK pathway as a Therapeutic Strategy for Triple-Negative Breast Cancer. Invited. Kyoto, JP.
- 2012. Targeting ERK as a Therapeutic Strategy for Triple-Negative Breast Cancer. Invited. Milwaukee, WI, US.
- 2012. Targeting ERK as a Therapeutic Strategy for Triple-Negative Breast Cancer. Invited. Mobile, AL, US.
- 2012. Targeting ERK as a Therapeutic Strategy for Triple-Negative Breast cancer. Invited. Houston, TX, US.
- 2012. Targeting ERK as a Therapeutic Strategy for Triple-Negative Breast Cancer. Invited. Oklahoma City, OK, US.
- 2012. Development of Targeted Therapy for ERK pathway in Triple-Negative Breast Cancer. Invited. Toledo, OH, US.
- 2011. Development of Targeted therapy for ERK Pathway in Triple-Negative Breast Cancer. Invited. Cleveland, OH, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | MELK Inhibition as a Strategic Approach to Target Cancer Stem Cells and Enhance Radiation Efficacy in Aggressive Breast Cancers |
| Funding Source: | 2025 Multidivisional Shark Tank Award |
| Role: | Co-PI |
| Date: | 2025 - 2028 |
| Title: | Targeting of Cancer Stem cells by inhibition of MELK in Aggressive Breast Cancers |
| Funding Source: | CPRIT -IIRA |
| Role: | PI |
| ID: | RP250101 |
| Date: | 2025 - Present |
| Title: | Evaluating A PEA-15-Based Repebody in Models of Metastatic Triple-negative Breast Cancer - LOI |
| Funding Source: | METAvivor |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | Dual Role of PEA-15 (phosphoprotein enriched in astrocytes) in Aggressive Breast Cancers |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2025 - 2029 |
| Title: | Targeting of Cancer Stem cells by inhibition of MELK in Aggressive Breast Cancers |
| Funding Source: | American Cancer Society |
| Role: | PI |
| ID: | RSG-1242764 |
| Date: | 2025 - 2026 |
| Title: | Targeting MELK kinase to inhibit Stage IV Metastatic Triple-Negative Breast Cancer (Top 20% LOI invited to apply) |
| Funding Source: | Metavivor |
| Role: | PI |
| ID: | FP00023585 |
| Date: | 2024 - 2026 |
| Title: | Deciphering the role of MELK in tumor stemness and immune microenvironment in models of aggressive breast cancer |
| Funding Source: | ACS |
| Role: | PI |
| ID: | FP00023945 |
| Date: | 2024 - 2026 |
| Title: | A novel MELK-DKK1 pathway regulates stemness in Aggressive Breast Cancers - MD Anderson Bridge Funds |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Cover the salary and fringe increase of the Postdoctoral Fellow |
| Funding Source: | 2023 Boot Walk Funding Award |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | A novel MELK-DKK1 pathway regulates stemness in Aggressive Breast Cancers |
| Funding Source: | NIH |
| Role: | PI |
| ID: | FP00021646 |
| Date: | 2024 - 2025 |
| Title: | Role of MELK as a novel therapeutic target in aggressive breast cancers |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Date: | 2024 - 2024 |
| Title: | IBC Zero balance ideas |
| Funding Source: | State of Texas Grant for Rare and Aggressive Breast Cancer |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | Local delivery of engineered extracellular vesicles loaded with anti-miRNAs to target breast cancer liver metastasis |
| Funding Source: | Yosemite American Cancer Society Award |
| Role: | Co-I |
| ID: | 1332955 |
| Date: | 2024 - 2029 |
| Title: | MELK as a Driver of Progression and Metastasis in Aggressive Breast Cancers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | Targeting MELK kinase to inhibit Stage IV Metastatic Triple-Negative Breast Cancer |
| Funding Source: | Breast Cancer Alliance |
| Role: | PI |
| Date: | 2024 - 2027 |
| Title: | Targeting of Cancer Stem cells by inhibiting MELK in Aggressive Breast Cancers |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| ID: | RSG-17-205-01-TBG |
| Date: | 2024 - 2024 |
| Title: | The Role of MELK/DKK1 pathway as a target in Inflammatory Breast Cancer Growth |
| Funding Source: | Cathy Rain Smith |
| Role: | PI |
| Date: | 2023 |
| Title: | Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers- Dr. Mughees Mohd |
| Funding Source: | Zeta Tau Alpha |
| Role: | Mentor |
| Date: | 2023 - 2025 |
| Title: | Inflammatory Breast cancer MRP Core Funding |
| Funding Source: | State of Texas Grant for Rare and Aggressive Breast Cancer |
| Role: | Co-I |
| Date: | 2023 - 2024 |
| Title: | 2023 Bootwalk |
| Funding Source: | MD Anderson Boot walk to End cancer |
| Role: | PI |
| Date: | 2023 |
| Title: | MIDDLE SCHOOL CAMP IN ONCOLOGY AT MD ANDERSON (MS-COMDA) |
| Funding Source: | 2023 Governor’s Summer Merit Program |
| Role: | Co-PI |
| Date: | 2023 - 2028 |
| Title: | MELK as a Driver of Progression and Metastasis in Aggressive Breast Cancers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | Development of mutant PEA-15 as a novel therapeutic for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | PEA-15 Gene Therapy for Aggressive Breast Cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | The Role of MELK in Stromal Reorganization of Aggressive Breast Cancers |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | BC220287 |
| Date: | 2023 - 2025 |
| Title: | Understanding the mechanism of phosphorylated PEA-15 in mediating protumor effects in triple-negative breast cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2023 - 2024 |
| Title: | Substance P receptor antagonism as a novel strategy to enhance doxorubicin (Dox)-mediated anti-tumor efficacy and prevent Dox-induced cardiotoxicity in triple negative cancer |
| Funding Source: | Institutional Research Grant |
| Role: | Consultant |
| Date: | 2023 - 2023 |
| Title: | The role of cytokine-mediated networks in aggressive breast cancers |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Co-PI |
| Date: | 2023 - 2026 |
| Title: | Targeting of Cancer Stem cells by inhibition of MELK in Aggressive Breast Cancers |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | The Role of MELK/DKK1 in promoting M2 Polarization in Inflammatory Breast Cancer Growth |
| Funding Source: | IBC Program Team Science Award |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | Role of Maternal Embryonic Leucine Zipper Kinase as a novel therapeutic target in aggressive breast cancers |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | Therapeutic Targeting of the Novel PEA-15/IL-8 pathway for triple-negative breast cancer |
| Funding Source: | The Andrew Sabin Family Foundation |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | Role of Soluble E-cadherin in Brain Metastatic Breast Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Date: | 2022 - 2023 |
| Title: | Role of a novel selective MELK inhibitor in Breast Cancer Brain metastasis |
| Funding Source: | UT Austin/MD Anderson Cancer Center Collaborative Pilot Projects Grant |
| Role: | Co-PI |
| Date: | 2022 - 2022 |
| Title: | MELK as a Driver of Inflammatory Breast Cancer progresion and Metastasis |
| Funding Source: | MD Anderson Cancer Center - Bridge Funding |
| Role: | PI |
| Date: | 2022 - 2022 |
| Title: | Therapeutic Targeting of the Novel PEA-15/IL-8 pathway for triple-negative breast cancer |
| Funding Source: | 2022 The Andrew Sabin Family Foundation Fellowship |
| Role: | PI |
| Date: | 2022 - Present |
| Title: | MELK as a Novel Therapeutic Target in Metastatic Breast Cancer |
| Funding Source: | METAvivor |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | Characterizing sEcad in brain metastatic breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | CO-I |
| Date: | 2021 - 2024 |
| Title: | MELK as a Driver of Inflammatory Breast Cancer Progression and Metastasis |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| Date: | 2021 - Present |
| Title: | MELK as a Driver of Inflammatory Breast Cancer Progression and Metastasis |
| Funding Source: | Morgan Welch Inflammatory Breast cancer Program |
| Role: | Co-PI |
| Date: | 2021 - 2024 |
| Title: | MELK Inhibition: A novel therapeutic strategy to treat inflammatory Breast Cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | Role of MELK as a novel therapeutic target in aggressive breast cancers |
| Funding Source: | Elsa Pardee Foundation |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | The Role of Early Growth Response 1 (EGR1) in TNBC metastasis |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | MELK as a Driver of Inflammatory Breast Cancer Progression and Metastasis |
| Funding Source: | Breast Cancer Alliance |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Development of mutant PEA-15 as a therapeutic strategy for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Date: | 2021 - 2024 |
| Title: | MELK as a Driver of Inflammatory Breast Cancer Progression and Metastasis |
| Funding Source: | METAvivor |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Determine the biological role of Mcl-1 in inflammatory breast cancer tumorigenicity |
| Funding Source: | 2020 Boot Walk Funding |
| Role: | Mentor |
| ID: | 2020 Boot Walk Funding Award |
| Date: | 2020 - 2021 |
| Title: | Role of a novel second-generation MELK-selective inhibitor in inflammatory breast cancer |
| Funding Source: | 2020 Boot Walk Funding |
| Role: | Mentor |
| ID: | Mentor - 2019 Boot Walk Funding Award |
| Date: | 2020 - 2023 |
| Title: | Drug Discovery of Potent Inhibitors of Maternal Embryonic Leucine Zipper Kinase as Targeted therapies for Triple Negative Breast Cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Principal Investigator-MDACC |
| Date: | 2020 |
| Title: | Inflammatory Breast Cancer Research |
| Funding Source: | Morgan Welch Inflammatory Breast cancer Program |
| Role: | Mentor |
| ID: | 2020 Zeta Tau Alpha Houston Alumnae Association Fellowship in Inflammatory Breast Cancer - Moises Tacam |
| Date: | 2019 - 2020 |
| Title: | Advancing Potent Inhibitors of Maternal Embryonic Leucine Zipper Kinase into Targeted Therapies for TNBC |
| Funding Source: | Elsa U Pardee Foundation |
| Role: | Principal Investigator-MDACC |
| ID: | Elsa U Pardee Foundation |
| Date: | 2019 - 2021 |
| Title: | Drug Discovery of Potent Inhibitors of Maternal Embryonic Leucine Zipper Kinase as Targeted therapies for Triple Negative Breast Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2019 - 2022 |
| Title: | Aspartate/Aspergine Beta Hydroxylase (ASPH): a novel therapeutic target for overcoming drug-resistant in metastatic Triple Negative Breast Cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | CO-I |
| ID: | CPRIT- IIRA (Investigator Initiated Research Award |
| Date: | 2019 - 2024 |
| Title: | Development of mutant PEA-15 as a therapeutic strategy for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2019 - 2024 |
| Title: | Targeting MELK in triple negative breast cancer metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 12723128 |
| Date: | 2019 - 2022 |
| Title: | Drug Discovery of Potent Inhibitors of Maternal Embryonic Leucine Zipper Kinase as Targeted therapies for Triple Negative Breast Cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Principal Investigator-MDACC |
| Date: | 2019 - 2022 |
| Title: | Targeting MELK in triple negative breast cancer metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2019 - 2021 |
| Title: | Advancing Potent Inhibitors of Maternal Embryonic Leucine Zipper Kinase into Targeted Therapies for TNBC |
| Funding Source: | The Andrew Sabin Family Foundation |
| Role: | PI |
| ID: | 11476314 |
| Date: | 2018 - 2021 |
| Title: | Modulation of PEA15 as a novel therapeutic approach in TNBC |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Role of FLI1 in ERK isoform specific regulation in Inflammatory Breast Cancer |
| Funding Source: | Morgan Welch IBC Program Seed Funding Award |
| Role: | PI |
| ID: | 105655-73 |
| Date: | 2018 - 2023 |
| Title: | Development of mutant PEA-15, a regulator of Beta-catenin, as a therapeutic gene for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Date: | 2018 - 2021 |
| Title: | Covalent inhibition of ERK recruitment: a new strategy to target tumor initiation and metastasis in TNBC |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| Date: | 2018 - 2022 |
| Title: | Understanding the role of MCl1 in MAPK driven tumors in Triple Negative Breast Cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| ID: | RSG -17-205-01-TBG |
| Date: | 2017 - 2018 |
| Title: | Role of ERK in Inflammatory Breast Cancer |
| Funding Source: | Morgan Welch IBC Program Seed Funding Award |
| Role: | Investigator |
| ID: | 105655-73 |
| Date: | 2017 - 2022 |
| Title: | MELK: a novel therapeutic target for triple negative breast cancer metastasis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | MultiPI 1R01 CA205419-01 |
| Date: | 2017 - 2018 |
| Title: | Investigating the regulation and function of a mechanosensor in TNBC |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R21 |
| Date: | 2017 - 2020 |
| Title: | MELK: a novel therapeutic target for triple negative breast cancer metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2017 - 2020 |
| Title: | Understanding the role of MCl1 in MAPK driven tumors in Triple Negative Breast Cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Investigating the regulation and function of a mechanosensor in TNBC |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | R21 |
| Date: | 2016 - 2019 |
| Title: | Overcoming MEK Resistance in TNBC by targeting Mcl-1, an anti-apoptotic protein |
| Funding Source: | MDACC-IRG |
| Role: | PI |
| Date: | 2016 - 2021 |
| Title: | Development of mutant PEA-15, a regulator of Beta-catenin, as a therapeutic gene for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA211978-01 |
| Date: | 2016 - 2017 |
| Title: | TRPM7 Kinase domain a new therapeutic target for suppressing metastasis of TNBC |
| Funding Source: | Bayer Innovation Experimental Plan |
| Role: | PI |
| Date: | 2016 - 2021 |
| Title: | A Comprehensive Kinome-Based Strategy for Developing Targeted Triple Negative Breast Cancer Therapies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP160656 |
| Date: | 2016 - 2021 |
| Title: | MELK: a novel therapeutic target for triple negative breast cancer metastasis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | MultiPI 1R01 CA205419-01 |
| Date: | 2016 - 2018 |
| Title: | Overcoming Acquired resistance to MEK Inhibitors in triple-negative breast cancer by targeting Mcl-1, an anti-apoptotic protein |
| Funding Source: | Sabin Fellowship |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | A Novel Therapeutic Target for Triple Negative Breast Cancer Metastasis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP160329 |
| Date: | 2016 - 2019 |
| Title: | MELK: A Novel Therapeutic Target for Triple Negative Breast Cancer Metastasis |
| Funding Source: | MDACC |
| Role: | PI |
| Date: | 2015 - 2017 |
| Title: | Project #4: Therapeutic effects of ERK1 and ERK2 suppression in triple-negative breast cancer experimental metastasis model: monitoring of CTC in experimental mouse model |
| Funding Source: | Angle |
| Role: | PI |
| ID: | CS2015-13015504-RM |
| Date: | 2013 - 2018 |
| Title: | Development of PEA15 as a targeted therapeutic gene for TNBC |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01-CA127562 |
| Date: | 2013 - 2017 |
| Title: | R00 Pathway to Independence Award NIH/NCITargeted therapy for ERK Pathway in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R00CA139006 |
| Date: | 2013 - 2019 |
| Title: | MD Anderson Cancer Center Start-up Fund |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
| Date: | 2011 - 2014 |
| Title: | Preclinical Development of a JNK-Targeted Therapy for Triple-Negative Breast Cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Mentor |
| ID: | KG111170 |
| Date: | 2009 - 2013 |
| Title: | K99 Pathway to Independence Award NIH/NCI/Development of Targeted therapy for ERK Pathway in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1K99CA139006-01A1 |
| Date: | 2006 - 2009 |
| Title: | PEA-15 as a Therapeutic Target for Enhanced Sensitization to Paclitaxel in Metastatic Breast Cancer |
| Funding Source: | Susan G. Komen Breast Cancer Foundation |
| Role: | Postdoctoral Fellow |
| ID: | Postdoctoral Fellow/PDF79906 01 |
| Date: | 2005 - 2006 |
| Title: | BettyAnn Asche-Murray Fellowship |
| Funding Source: | University of Texas MD Anderson Cancer Center |
| Role: | Postdoctoral Fellow |
| Date: | 2002 - 2002 |
| Title: | National Science Foundation (NSF)/Ministry of Education, Ministry of Culture, Sports, Science and Technology in Japan (MEXT) |
| Funding Source: | National Science Foundation (NSF) |
| Role: | Graduate Student |
| Title: | Preliminary Data Acquistion |
| Funding Source: | 2021 Bootwalk Funding |
| Role: | PI |
| Title: | R01 grant application, titled "Localized Chemotherapeutic Delivery via Biodegradable Bone Cement for Image-Guided, Minimally Invasive Treatment of Breast Cancer Spine Metastases |
| Funding Source: | NIH |
| Role: | Co-I |
| Title: | Mechanistic insights into DKK1-mediated tumor growth and metastasis in aggressive breast cancers |
| Funding Source: | DOD |
| Role: | PI |
| Title: | MELK Inhibition as a Strategic Approach to Target Cancer Stem Cells and Enhance Radiation Efficacy in Aggressive Breast Cancers |
| Funding Source: | Elsa Pardee |
| Role: | PI |
| Title: | Druggable Mechanisms of Breast cancer Metastsis |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Program Leader |
| ID: | MRP |
| Title: | Characterizing sEcad in brain metastatic breast cancer |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| Title: | Targeting the PEA-15/IL-8 pathway for triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | Substance P receptor antagonism, as a novel therapeutic option for triple negative breast cancer and a tool to prevent chemotherapy induced cardiotoxicity |
| Funding Source: | CPRIT |
| Role: | CO-I |
| Title: | MELK as a Driver of Progression and Metastasis in Aggressive Breast Cancers |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | The Role of a novel selective MELK inhibitor in Breast Cancer Brain metastasis |
| Funding Source: | UT Austin/MD Anderson Cancer Center Collaborative Pilot Projects Grants |
| Role: | PI |
| Title: | MELK as a Driver of Progression and Metastasis in Aggressive Breast Cancers |
| Funding Source: | CPRIT |
| Role: | PI |
| Title: | Harnessing PEA-15 to Target Aggressive Breast Cancers: Implications for TNBC and IBC Treatment |
| Funding Source: | CPRIT |
| Role: | PI |
| Title: | Local delivery of extracellular vesicles loaded with anti-miRNAs secreted by engineered T cells to target triple-negative breast cancer: a novel strategy |
| Funding Source: | Department of Defense (DOD) |
| Role: | CO-I |
| Title: | Targeted therapy harnessing the MAPK pathway for TNBC |
| Funding Source: | Emerson Collective |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Hu X, Xiong Y, Villodre ES, Zhang H, Longa IR, Song J, Fowlkes N, Krishnamurthy S, Rylander M, Bartholomeusz C, Tripathy D, Woodward WA, Chen J, Debeb BG. Soluble E-cadherin-CXCL1-CXCR2 Axis as a Therapeutic Vulnerability in Inflammatory Breast Cancer Brain Metastasis. Neuro Oncol, 2026. e-Pub 2026. PMID: 41578012.
- Mughees, M, Tacam, MJ, Tan, AW, Pitner, MK, Iles, LR, Hu, XD, Schlee Villodre, E, Debeb, BG, Kogawa, T, Lim, B, Layman, RM, Woodward, W, Ueno, NT, Tripathy, D, Krishnamurthy, S, Qi, Y, Pusztai, L, Wang, J, Gandhi, VV, Bartholomeusz, G, Bartholomeusz, C. Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. Molecular cancer therapeutics 24(9):1453-1465, 2025. e-Pub 2025. PMID: 40358476.
- Hu X, Xiong Y, Villodre ES, Zhang H, Song J, Fowlkes N, Krishnamurthy S, Rylander M, Bartholomeusz C, Tripathy D, Woodward WA, Chen J, Debeb BG. Soluble E-cadherin Drives Brain Metastasis in Inflammatory Breast Cancer. bioRxiv, 2025. e-Pub 2025. PMID: 40667060.
- Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz C. Maternal embryonic leucine zipper kinase is associated with metastasis in triple-negative breast cancer. Cancer Res Commun 3(6):1078-1092, 2023. e-Pub 2023. PMID: 37377604.
- Park J, Tacam MJ, Chauhan G, Cohen EN, Gagliardi M, Iles LR, Ueno NT, Battula VL, Sohn YK, Wang X, Kim HS, Krishnamurthy S, Fowlkes NW, Green MM, Bartholomeusz GA, Tripathy D, Reuben JM, Bartholomeusz C. Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Res Treat 189(2):333-345, 2021. e-Pub 2021. PMID: 34241740.
- Xie X, Lee J, Liu H, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, Ueno NT. Birinapant Enhances Gemcitabine's Anti-tumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. Mol Cancer Ther 20(2):296-306, 2021. e-Pub 2021. PMID: 33323457.
- Gagliardi M, Pitner MK, Park J, Xie X, Saso H, Larson RA, Sammons RM, Chen H, Wei C, Masuda H, Chauhan G, Kondo K, Tripathy D, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz C. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Sci Rep 10(1):8537, 2020. e-Pub 2020. PMID: 32444778.
- Dilruba S, Grondana A, Schiedel AC, Ueno NT, Bartholomeusz C, Cinatl J, McLaughlin KM, Wass MN, Michaelis M, Kalayda GV. Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells 9(2), 2020. e-Pub 2020. PMID: 32102425.
- Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 176(1):251, 2019. e-Pub 2019. PMID: 30982934.
- Sammons RM, Perry NA, Li Y, Cho EJ, Piserchio A, Zamora-Olivares DP, Ghose R, Kaoud TS, Debevec G, Bartholomeusz C, Gurevich VV, Iverson TM, Giulianotti M, Houghten RA, Dalby KN. A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation. ACS Chem Biol 14(6):1183-1194, 2019. e-Pub 2019. PMID: 31058487.
- Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 175(2):339-351, 2019. e-Pub 2019. PMID: 30826934.
- Jose J, Tavares CDJ, Ebelt ND, Lodi A, Edupuganti R, Xie X, Devkota AK, Kaoud TS, Van Den Berg CL, Anslyn EV, Tiziani S, Bartholomeusz C, Dalby KN. Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth. ACS Med Chem Lett 8(10):1072-1076, 2017. e-Pub 2017. PMID: 29057053.
- Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT. EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget 8(40):67904-67917, 2017. e-Pub 2017. PMID: 28978083.
- Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M. IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget 8(23):36936-36949, 2017. e-Pub 2017. PMID: 28415808.
- Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Wang J, Gray NS, Dalby KN, Bartholomeusz C, Ueno NT. c-Jun N-terminal kinase promotes stem cellphenotype in triple-negative breast cancer through up-regulation of Notch1 via activation of c-Jun. Oncogene 36(ISSN 0950-9232):2599-2608, 2017. e-Pub 2017. PMID: 27941886.
- Edupuganti R, Taliaferro JM, Wang Q, Xie X, Cho EJ, Vidhu F, Ren P, Anslyn EV, Bartholomeusz C, Dalby KN. Discovery of a Potent Inhibitor of MELK that inhibits Expression of the Anti-apoptotic Protein Mcl-1 and TNBC Cell Growth. Bioorg Med Chem 25(9):2609-2616, 2017. e-Pub 2017. PMID: 28351607.
- Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor Activity of KW-2450 Against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther 14(12):2687-99, 2015. e-Pub 2015. PMID: 26443806.
- Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT. MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther 14(12):2773-81, 2015. e-Pub 2015. PMID: 26384399.
- Boulbes DR, Chauhan GB, Jin Q, Bartholomeusz C, Esteva FJ. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat 151(3):501-13, 2015. e-Pub 2015. PMID: 25971596.
- Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, Esteva FJ. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol 9(3):586-600, 2015. e-Pub 2015. PMID: 25435280.
- Xie X, Tang H, Pengliu, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT, Xie X. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett 356(2 Pt B):374-81, 2015. e-Pub 2015. PMID: 25304382.
- Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer 6(12):1306-19, 2015. e-Pub 2015. PMID: 26640591.
- Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat 146(2):259-72, 2014. e-Pub 2014. PMID: 24916181.
- Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 2014. e-Pub 2014. PMID: 24703838.
- Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H, Ueno NT. Ink4a/Arf-/- and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49F- quiescent cells. Oncogene 33(4):440-8, 2014. e-Pub 2014. PMID: 23376849.
- Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN, Ueno NT. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther 12(6):1099-111, 2013. e-Pub 2013. PMID: 23543364.
- Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):331-45, 2012. e-Pub 2012. PMID: 23073759.
- Bartholomeusz, C, Lee, J, Ueno, NT. PEA15 (phosphoprotein enriched in astrocytes 15). Atlas of Genetics and Cytogenetics in Oncology and Hematology 16(10):732-735, 2012. e-Pub 2012.
- Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther 11(2):360-9, 2012. e-Pub 2012. PMID: 22144664.
- Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobágyi GN. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 17(6):766-74, 2012. e-Pub 2012. PMID: 22584435.
- Lee J, Bartholomeusz C, Krishnamurthy S, Liu P, Saso H, Lafortune TA, Hortobagyi GN, Ueno NT. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin. Oncogenesis 1:e22, 2012. e-Pub 2012. PMID: 23552738.
- Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NT. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol 122(3):641-7, 2011. e-Pub 2011. PMID: 21652059.
- Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist 16(7):956-65, 2011. e-Pub 2011. PMID: 21712485.
- Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NT. Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. J Cancer 2:435-42, 2011. e-Pub 2011. PMID: 21850211.
- Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol 100(3):449-57, 2010. e-Pub 2010. PMID: 20455002.
- Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 16(6):1802-11, 2010. e-Pub 2010. PMID: 20215547.
- Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 68(22):9302-10, 2008. e-Pub 2008. PMID: 19010903.
- Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 7(7):1846-50, 2008. e-Pub 2008. PMID: 18644997.
- Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6(8):2168-77, 2007. e-Pub 2007. PMID: 17671085.
- Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67(12):5779-88, 2007. e-Pub 2007. PMID: 17575145.
- Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther 6(1):227-35, 2007. e-Pub 2007. PMID: 17218636.
- Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res 9(4):R41, 2007. e-Pub 2007. PMID: 17612393.
- Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NT. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther 13(5):451-9, 2006. e-Pub 2006. PMID: 16294215.
- Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 25(1):79-90, 2006. e-Pub 2006. PMID: 16170361.
- Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res 65(18):8406-13, 2005. e-Pub 2005. PMID: 16166319.
- Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 62(22):6712-6, 2002. e-Pub 2002. PMID: 12438271.
- Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 2001. e-Pub 2001. PMID: 11454891.
- Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 6(1):250-9, 2000. e-Pub 2000. PMID: 10656456.
Review Articles
- Pitner MK, Taliaferro JM, Dalby KN, Bartholomeusz C. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opin Ther Targets 21(9):849-859, 2017. e-Pub 2017. PMID: 28764577.
- Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):121-30, 2012. e-Pub 2012. PMID: 22239433.
Other Articles
- Xie, X, Chauhan, GB, Edupuganti, R, Kogawa, T, Park, J, Tacam, MJ, Tan, AW, Mughees, M, Vidhu, F, Liu, D, Taliaferro, JM, Pitner, MK, Browning, LS, Lee, JH, Bertucci, F, Shen, Y, Wang, J, Ueno, NT, Krishnamurthy, S, Hortobagyi, GN, Tripathy, D, Van Laere, SJ, Bartholomeusz, G, Dalby, KN, Bartholomeusz, C Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Research Communications 4(1):236, 2024. PMID: 38282551.
- Bartholomeusz C, Gonzalez-Angulo AM . Targeting the PI3K signaling pathway in cancer therapy:121-30, 2012. PMID: 22239433.
Abstracts
- Bartholomeusz C. MELK controls stromal components through fibronectin modulation in highly aggressive breast cancers. 2024 San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
- Tan, A, Mughees,M, Woodward,W, Tripathy,D, Fowlkes, N, Bartholomeusz,C. PEA-15 phosphorylation mediates pro-tumor effects by promoting β-catenin activity in TNBC - Late Breaking Abstract. 2024 AACR Annual Meeting, 2024.
- Bartholomeusz C. Combined inhibition of MCL-1 and MEK reduces tumor growth in a triple-negative/inflammatory breast cancer, MEK-resistant xenograft mouse model. 2024 AACR Annual Meeting, 2024.
- Mohd Mughees, Alex Tan, Iles L, White M, Tripathy D, Krishnamurthy S, Wang J, Woodward W, Bartholomeusz G, Bartholomeusz C. Combined inhibition of MCL-1 and MEK reduces tumor growth in a MEK-resistant xenograft mouse model of triple-negative/inflammatory breast cancer- My Postdoctoral Fellow received the People's Choice Poster Award at the 2024. Trainee Recognition Day 2024, 2024.
- Mughees M, Tacam M, Tan A, White M, Debeb BG, Villodre ES, Hu X, Tripathy D, Woodward W, Layman RM, Bartholomeusz G, Bartholomeusz AC. A selective MCL-1 inhibitor AZD5991 showed tumor regression in a triple-negative. 2023 San Antonio Breast Cancer Symposium, 2023.
- Ma W, Zhao L, Devi G, student G, Coffer L, Krishnamurthy1 S, Alexander A, Kai M, Le-Petross C, Debeb BG, Bartholomeusz C, Coffer L, Zhang J, Song X, Futreal A, Tumor Initiative TR, Wang M, Ueno N, Layman R, Lucci A, Wang J, Woodward WA. Building genomic and transcriptomic data among African American patients with triple-negative inflammatory breast cancer. 2023 San Antonio Breast Cancer Symposium, 2023.
- Mughees M, Tacam M, Hector Gonzalez AT, Villodre ES, Debeb BG, Tripathy D, Bartholomeusz G, Lee J, Dalby K, Bartholomeusz C. Novel second-generation selective MELK inhibitor reduces tumor growth in a triple-negative inflammatory breast cancer xenograft model. Translational research category for the Oral Competition of Trainee Research Day 2023 -Received first Place, 2023. e-Pub 2023.
- Mughees M, Tacam M, Tan A, Gonzalez H, Villodre ES, Debeb BG, Tripathy D, Bartholomeusz G, Lee J, Dalby K, Bartholomeusz C. Therapeutic potential of second-generation MELK-selective inhibitor in aggressive breast cancers. 7th International Inflammatory Breast Cancer Symposium: Understanding and Managing Aggressive Breast Cancer', 2022. e-Pub 2022.
- Mughees M, Tacam M, Tan A, Gonzalez H, Villodre ES, Debeb BG, Tripathy D, Bartholomeusz G, Lee J, Dalby K, Bartholomeusz C. Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers. 2022 San Antonio Breast Cancer Symposium, 2022. e-Pub 2022.
- Hu X, Xiong Y, Villodre ES, Song J, Manyam GC, Tacam M, Wang J, Bartholomeusz C, Tripathy D, Ueno NT, Savitri Krishnamurthy WAW, G Debeb JCB. Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer. 2022 San Antonio Breast Cancer Symposium – Oral Presentation, 2022. e-Pub 2022.
- Mughees M, Tacam M, Tan A, Iles L, White M, Tripathy D, Bartholomeusz G, Bartholomeusz AC. Combination treatment with a MCL1 Inhibitor AZD5991 overcomes resistance to MEK inhibitor in TNBC cells. 2022 AACR Meeting, 2022. e-Pub 2022.
- Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Vidhu FNU, Liu DD, Taliaferro JM, Pitner MK, Shen Y, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby K, Bartholomeusz AC. Maternal embryonic leucine zipper kinase is associated with metastasis in triple-negative breast cancer. 2021 SABC Meeting, 2021. e-Pub 2021.
- Yun Xiong XH, Villodre ES, Song J, Manyam GC, Tacam M, Wang J, Bartholomeusz C, Tripathy D, Woodward WA, Chen J, Debeb BG. Soluble E-cadherin: a novel prognostic biomarker and driver of anoikis escape in inflammatory breast cancer. 2021 Annual Postdoctoral Science Symposium - Oral, 2021. e-Pub 2021.
- 5Gonzalez, Tacam HC, Mughees MJ, Lee MN, Dalby J, and Bartholomeusz KN, Chandra. A Novel Second-generation MELK specific inhibitor targets triple negative inflammatory breast cancer (TN-IBC. 2021 Summer Experience, 2021. e-Pub 2021.
- Sohoni S, Nguyen T, Shin DH, Fan X, Jiang H, Gupta S, Ossimetha A, Yi Y, Bartholomeusz C, Alonso M, Fueyo J, Gomez-Manzano AC. Targeting the immunosuppressive microenvironment of metastatic breast cancer with viroimmunotherapy. 2021 AACR Meeting, 2021. e-Pub 2021.
- Xie X, Lee J, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, T Ueno AN. Birinapant enhances gemcitabine’s anti-tumor efficacy in triple-negative breast cancer by inducing intrinsic pathway–dependent apoptosis. 2020 AACR Annual Meeting, 2020. e-Pub 2020.
- Gagliardi M, Tacam M, Iles L, Qi Y, Pusztai4 L, Tripathy D, Bartholomeusz G, Bartholomeusz C. Mechanism of MEK inhibitor resistance in triple-negative breast cancer. 2020 AACR Annual Meeting, 2020. e-Pub 2020.
- Gagliardi M, Iles L, Qi Y, Pusztai L, Tripathy D, Bartholomeusz G, Bartholomeusz C. Function of UCPs (Uncoupling proteins) in MEK Inhibitor resistance triple-negative breast cancer. APSS (Annual Postdoctoral Science Symposium)Third Place Oral Presentation in the Basic Science Category, 2019. e-Pub 2019.
- Tan A, Gagliardi M, Tacam M, Bartholomeusz C. Exploring MEK-inhibitor resistant triple-negative breast cancer cells, and investigating MCL-1 inhibition as a pathway to overcoming resistance. Summer Undergraduate Research Program (SURP), 2019. e-Pub 2019.
- Park J, Chauhan G, Cohen EN, Ueno NT, Battula VL, Tripathy D, Reuben JM, Bartholomeusz C. PEA15-AA, an unphosphorylatable mutant of PEA15, as a novel therapeutic gene for triple-negative breast cancer. 2018 SABCS Annual Meeting, 2018. e-Pub 2018.
- Gagliardi M, Chauhan G, Pitner MK, Iles L, Qi Y, Pusztai L, Tripathy D, Bartholomeusz G, Bartholomeusz C. Overcoming MEK Inhibitor resistance in triple-negative breast cancer by targeting myeloid cell leukemia-1 (MCL1), an anti-apoptotic protein. 2018 SABCS Annual Meeting, 2018. e-Pub 2018.
- W Puerta Martinez W, A Rivera F&, Nguyen Y&, Fan T&, Shifat X&, Belayat Hossain R&, Bartholomeusz M&, F Frederick C&, Jiang L&, Gomez-Manzano H&, Candelaria. Partial reversion of the tumor immunosuppressed environment by oncolytic adenoviruses armed with positive stimulators of the immune synapsis in breast cancer. Proc Annu Meet Assoc Cancer Res, 2018. e-Pub 2018.
- Park J, Chauhan G, Cohen EN, Lee J, Ueno NT, Battula VL, Tripathy D, Reuben JM, Bartholomeusz C. Non-phosphorylatable PEA15 reverts epithelial-mesenchymal transition (EMT) induced in triple negative breast cancer by regulating IL-8 expression. 2018 APSS (Annual Postdoctoral Science Symposium), 2018. e-Pub 2018.
- Park J, Cohen EN, Lee J, Ueno NT, Tripathy D, Reuben JM, Bartholomeusz C. PEA-15 (phosphoprotein enriched in astrocytes) regulates epithelial-mesenchymal transition and invasive behavior through it's phosphorylation in triple negative breast cancer. 2017 AACR Annual Meeting -Recipient of the AACR-Aflac Scholar-in-Training Award, 2017. e-Pub 2017.
- Xie X, Otsuka S, Chu K, Lu AY, Tripathy D, Dalby K, Hittelman WN, Laere SV, Bartholomeusz C, T Ueno AN. JNK signaling regulates tumor cell–tumor-associated macrophage cross-talk in triple-negative breast cancer. 2017 SABCS Annual Meeting, 2017. e-Pub 2017.
- Chiorazzo, MG, Vasquez, KM, Bartholomeusz G, Bartholomeusz C, Dalby, KN. MELK influences repair of DNA interstrand crosslinks in human breast cancer cells. CMCT syposium, 2017. e-Pub 2017.
- Park J, Cohen EN, Lee J, Ueno NT, Tripathy D, Reuben JM, Bartholomeusz C. PEA-15 (phosphoprotein enriched in astrocytes) regulates epithelial-mesenchymal transition and invasive behavior through it's phosphorylation in triple negative breast cancer. 2017 Trainee Recognition Day. * Selected as a finalist for Oral Presentation in the Basic Science Category, 2017. e-Pub 2017.
- Nguyen K, Sun J, Dasgupta A, Bartholomeusz C, Andreeff M, Battula VL. ST8SIA1 Regulates Tumorigenesis in Triple Negative Breast Cancer. 2016 SABCS Annual Meeting, 2016. e-Pub 2016.
- Park J, Cohen EN, Lee J, Ueno NT, Tripathy D, Reuben JM, Bartholomeusz C. PEA-15 (phosphoprotein enriched in astrocytes) regulates epithelial-mesenchymal transition and invasive behavior through it's phosphorylation in triple negative breast cancer. 2017 APSS Annual Meeting, 2016. e-Pub 2016.
- *Pitner MK, Saso H, Larson R, Sammons RM, Wei CC, Chauhan G, Kondo K, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz C. Silencing of ERK2 reverses EMT and suppresses the CSC phenotype, inhibiting lung metastasis in triple-negative breast cancer. 2016 AACR Annual Meeting (*Recipient of the AACR-Triple Negative Breast Cancer Foundation Scholar-in-Training Award), 2016. e-Pub 2016.
- Ebelt ND, Taveres CDJ, Xie X, Naguib YW, Jose J, Ruwona TB, Devkota AK, Park J, Kaoud TS, Anslyn EV, Chang JT, Cui Z, Bartholomeusz C, Dalby KN. KD06 is a novel anti-cancer drug that causes cell death in triple-negative breast cancer cell lines and tumor xenografts. 2016 AACR Annual Meeting, 2016. e-Pub 2016.
- *Torres-Adorno AM, Lee JJ, Kogawa T, Bartholomeusz C, Ordentlich P, Goodstal S, Lim B, Tripathy D, Ueno NT. The histone deacetylase inhibitor entinostat enhances the efficacy of the MEK inhibitor pimasertib against aggressive types of breast cancer through Noxa-mediated myeloid cell leukemia 1 degradation. 2015 San Antonio Breast Cancer Symposium (SABCS) (*Recipient of the Fourth Annual Zeta Tau Alpha Houston Alumni Association Fellowship in IBC Research, 11/2015), 2015. e-Pub 2015.
- Kaoud TS, Xie X, Park J, Tavares CDJ, Mitra S, Cano M, Sammons RM, Radwan MF, Bartholomeusz C, Dalby KN. TRPM7 kinase domain is involved in breast tumor cell metastasis. 2015 AACR Tumor Metastasis Conference 76(7), 2015. e-Pub 2015.
- Kogawa T, Liu DD, Chauhan GB, Taliaferro JM, Masuda H, Van Laere SJ, Bertucci F, Shen Y, Ueno NT, Dalby KN, Bartholomeuesz C. High MELK expression levels correlate with shorter overall survival in breast cancer. 2015 Gordon Research Conference on Mammary Gland Biology, 2015. e-Pub 2015.
- Kaoud TS, Xie X, Park J, Tavares CDJ, Mitra S, Cano M, Tseng C, Radwan MF, Bartholomeusz C, Dalby KN. Targeting the transient receptor potential-melastatin-like 7 (Trpm7) kinase domain with the first inhibitor, inhibited breast cancer cell migration, invasion and tumor metastasis. 2016 FASEB Journal 29(1), 2015. e-Pub 2015.
- *Xie X, Kaoud TS, Edupunganti R, Zhang T, Kogawa T, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Gray NS, Dalby KN, Bartholomeuesz C, Ueno NT. Suppression of triple-negative breast cancer tumorigenesis by targeting cancer stem cells through JNK/Notch1 signaling inhibition. 2015 AACR Annual Meeting (*Traininee Recognition day 5/2015 - * Recipient the Bayer HealthCare Pharmaceuticals, Inc. Award in Translational Research 2015) 75(15), 2015. e-Pub 2015.
- Kaoud TS, Xie X, Park J, Tavares CDJ, Mitra S, Cano M, Sammons RM, Radwan MF, Bartholomeusz C, Dalby KN. Inhibition of the TRPM7 kinase domain inhibits breast cancer cell migration and invasion and tumor metastasis. 2015 AACR Annual Meeting, 2015. e-Pub 2015.
- Kogawa T, Liu DD, Chauhan GB, Taliaferro JM, Masuda H, VanLaere S, Bertucci F, Shen Y, Ueno NT, Dalby KN, Bartholomeusz C. High MELK expression levels correlate with shorter overall survival in breast cancer. 2014 San Antonio Breast Cancer Symposium (SABCS), 2014. e-Pub 2014.
- Lee J, Bartholomeusz C, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in both HER2-overexpressing inflammatory and non-inflammatory breast cancer cells through FOXO3-mediated Bim1 expression. 2014 San Antonio Breast Cancer Symposium (SABCS), 2014. e-Pub 2014.
- Pitner MK, Kogawa T, Ueno NT, Bartholomeusz C. Mcl-1: a potential therapeutic target in triple-negative breast cancer. MDA Postodoctoral Symposium, 2014. e-Pub 2014.
- Pitner MK, Saso H, Wei C, Chen H, Kondo K, Ueno N, Bartholomeusz C. ERK2, but not ERK1, promotes cancer stem cell-like characteristics and EMT in triple-negative breast cancer. 2014 Gordon Research Conference on Mammary Gland Biology, 2014. e-Pub 2014.
- Xie X, Kaoud TS, Edupunganti R, Zhang T, Kogawa T, Chauhan GB, Gray NS, Bartholomeusz C, Dalby KN, Ueno N. JNK-IN-8: a novel covalent inhibitor targeting JNK signaling in triple-negative breast cancer. 2014 AACR Annual Meeting 74(19), 2014. e-Pub 2014.
- Xie X, Kaoud TS, EdupugantiR, Sammons RM, Hortobagyi GN, Ueno NT, Dalby KN, Bartholomeusz C. Preclinical development of JNK-targeted therapy for triple-negative breast cancer. 2013 AACR Annual Meeting 73(8), 2013. e-Pub 2013.
- Bartholomeusz D, Saso H, Dadbin A, Masuda H, Kogawa T, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. ERK2 rather than ERK1 contributes to EMT and metastatic potential in triple-negative breast cancer. AACR Annual Meeting 2013, 2013. e-Pub 2013.
- Bartholomeusz C, Dadbin A, Saso H, Kondo K, Smith PD, Hortobagyi GN, Ueno NT. The MEK inhibitor selumetinib (AZD 6244-ARRY-142886) prevents lung metastasis in a triple-negative breast cancer (TNBC) xenograft model. Proc Annu Meet Assoc Cancer Res (Late Breaking Abstract), 2012. e-Pub 2012.
- Bartholomeusz C, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Hortobagyi GN, Ueno NT. Selumetinib inhibits cancer stem cells by targeting the MAPK pathway in TNBC/IBC. Third International Inflammatory Breast Cancer conference, 2012. e-Pub 2012.
- Bartholomeusz C, Dadbin A, Kazansky A, Saso H, Hortobagyi GN. MEK inhibitor selumetinib (AZD6244 – ARRY-142886) promotes mesenchymal to epithelial transition in triple-negative breast cancer. Proc Annu Meet Assoc Cancer Res, 2011. e-Pub 2011.
- Bartholomeusz C, Saso H, Dadbin A, Kazuharu K and Hortobagyi GN. ERK2 promotes stem cell-like characteristics in triple-negative breast cancer. SanAntonio Breast Cancer Symposium (Poster Discussion), 2011. e-Pub 2011.
- Bartholomeusz C, Gonzalez-Angulo A, Liu P, Hayashi N, Hortobagyi GN, Ueno NT. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer. Proc Annu Meet Assoc Cancer Res, 2010. e-Pub 2010.
- Oishi T, Bartholomeusz C, Kazansky A, Akar U, Krishnamurthy S, Esteva FJ, Itamochi H, Ueno NT. ERK targeted therapy suppresses tumorigenicity in ovarian clear cell carcinoma and is modulated by ERK-binding protein PEA-15. Proc Annu Meet Assoc Cancer Res, 2010. e-Pub 2010.
- Oishi T, Bartholomeusz C, LaFortune T, Kazansky A, Zhang D, Itamochi H, Ueno NT. ERK-binding protein PEA-15 modulates ERK-targeted therapy in ovarian clear cell carcinoma. Proc Annu Meet Assoc Cancer Res, 2009. e-Pub 2009.
- Bartholomeusz C, Krishnamurthy S, Yuan LXH, Yamasaki F, Kazansky A, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in a breast cancer xenograft model by inhibiting tumor cell proliferation through increased cytoplasmic localization of activated ERK. Proc Annu Meet Assoc Cancer Res, 2009. e-Pub 2009.
- Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Proc Annu Meet Assoc Cancer Res, 2008. e-Pub 2008.
- Yamasaki F, Inoue N, Sudo T, Zhang D, Bartholomeusz C, Kurisu K, Hortobagyi GN, Ueno NT. Testis-related gene, MORC1, induces dysfunctional spindle assembly checkpoint, rendering paclitaxel resistance. Proc Annu Meet Am Assoc Cancer Res, 2007. e-Pub 2007.
- Chandra B, Daniel R, Caimiao W, Fumiyuki Y, Takeshi T, Hiroaki I, Seiji K, Liu Jinsong Ueno NT. Novel ERK regulator phosphoprotein PEA-15, which induces autophagy in human ovarian cancer cells is associated with prolonged overall survival in women with primary epithelial ovarian cancer. Proc Annu Meet Assoc Cancer Res and 11th Annual Trainee Recognition Day and Research Symposium, MD Anderson Cancer Center, 2007. e-Pub 2007.
- Bartholomeusz C, Symmans WF, Zhang P, Yamasaki F, Ginsberg MH, Ueno NT. High PEA-15 Expression is Associated with Low Tumor Grade in Breast Cancer. Proc Annu Meet Am Assoc Cancer Res, 2006. e-Pub 2006.
- Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NT. Adenovirus Type 5 E1A Gene Therapy for Ovarian Clear Cell Carcinoma. Proc Annu Meet Am Assoc Cancer Res, 2006. e-Pub 2006.
- Yamasaki F, Johansen MJ, Huang HL, Bartholomeusz C, Kurisu K, Hortobagyi GN, Ueno NT. Erlotinib Resistance and Phospho-Akt Activation in EGFR-Overexpressing Cancer Cells. Proc Annu Meet Am Assoc Cancer Res, 2006. e-Pub 2006.
- Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Cytoplasmic Sequestration of Activated ERK by PEA-15 Contributes to the Antitumor Effect of E1A in Ovarian Cancer. Proc Am Assoc Cancer Res, 2005. e-Pub 2005.
- Itamochi, H, Sudo, T, Takahashi, T, Bartholomeusz, C, Das, S, Terakawa, N, Travis, Ueno EA, NT. NT Reduction of radiation-induced lung toxicities by specific expression of Bcl-2 in normal cells. American Association of Cancer Research, 2004. e-Pub 2004.
- Bartholomeusz, C, Itamochi, H, Yuan, LH, Esteva, FJ, Wood, C, Terakawa, N, Hung, Ueno MA. Bcl-2 Antisense Oligonucleotide Overcoming Resistance to E1A Gene Therapy in Low-HER2-Expressing Ovarian Cancer. American Association of Cancer Research, 2004. e-Pub 2004.
- Bartholomeusz, C, Nitta M, T Ueno HSAN. Mechanism of E1A- induced Anti-tumor effect in Ovarian Cancer through PEA-15 (phospho-enriched in astrocytes). Proc Annu Meet Am Assoc Cancer Res, 2003. e-Pub 2003.
- Bartholomeusz, C, Anklesaria P, Wood CG, Hung M-C and Ueno NT. Mechanism of Resistance of E1A Gene Therapy in Ovarian Cancer by Phospho-Akt and Bcl-2. Annual Trainee Recognition Day and Research Symposium, MD Anderson Cancer Center, 2002. e-Pub 2002.
- Ueno NT, Anklesar P, Bartholomeusz C, Xia W, Li S, Hung M-C HLA. Systemic E1A gene Therapy Breast and Head/Neck Cancer. Proc Annu Meet Am Assoc Cancer Res, 2001. e-Pub 2001.
- Ueno NT, Bartholomeusz C, Xia W, Herrmann JL, Estrov Z, Shao RP, Yu D, Hung MC. E1A-mediated paclitaxel (taxol) sensitization in HER-2/neu-overexpressing ovarian cancer through apoptosis involving caspase-3 pathway. Proc Annu Meet Am Assoc Cancer Res, 1999. e-Pub 1999.
- Ueno NT, Bartholomeusz C, Herrmann J, Estrov Z, Shao R, Andreeff M, Price J, Paul R, Anklesaria P, Yu D, Hung MC. The E1A Phase I gene therapy for patients with breast and ovarian cancers: further characterization of molecular markers. Proceedings of the American Society of Gene Therapy, 1999. e-Pub 1999.
- Zinner R, Ueno NT, Bartholomeusz C, Xing X, Steck P, Hung MC. MMAC1gene therapy in breast cancer: suppression of tumorigenicity by inhibiting Akt-dependent anti-apoptosis activity. Proc Annu Meet Am Assoc Cancer Res, 1999. e-Pub 1999.
Patient Reviews
CV information above last modified March 06, 2026